Travere Therapeutics Announces FDA Accelerated Approval of FILSPARIᵀᴹ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

Alnylam plans $250m investment in Norton manufacturing facility, US

EC approves Incyte’s Minjuvi combo for follicular lymphoma

Many companies and businesses have viewed artificial intelligence (AI) as a tool for amplifying efficiency, such as automating simple tasks and making backend projects more efficient.

TSC Alliance Endowment Fund Invests in Aeovian Pharmaceuticals to Advance Development of an mTORC1 Selective Inhibitor for Tuberous Sclerosis Complex